Skip to content
OpenCapital
Get started

Inhibrx Biosciences, Inc. INBX Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Revenue-Miss by $1.1MDiluted EPS-$2.11Miss by $0.03
Revenue estimate$1.1M
EPS estimate-$2.08

Next report

Aug 12, 2026 (in a month)
EPS estimate-$2.28

Financials

Q4 2025

Income statement

See full
Revenue--100%
Operating income-$30.9M+38.1%
Net income-$32.8M—
EPS (diluted)-$2.11—

Balance sheet

See full
Cash & equivalents$124.2M-18.6%
Total debt$107.0M+1,230%
Total equity$8.0M-94.0%
Total assets$146.5M-19.0%

Cash flow

See full
Operating cash flow-$30.1M+31.1%
Free cash flow-$30.1M+31.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.15B+415%
Enterprise value$1.13B+1,344%
P/S883.8×-231×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio3.9×0.0×

Versus estimates

Revenue

Q2 2025$1.3MQ4 2024$100.0K

Diluted EPS

Q1 2026-$2.15Beat by $0.22
Q4 2025-$2.11Miss by $0.03
Q3 2025-$2.28Miss by $0.20Q2 2025-$1.85Beat by $1.07Q1 2025-$2.80Miss by $0.25Q4 2024-$3.09Miss by $0.21

Ask the moment Inhibrx Biosciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Inhibrx Biosciences, Inc. report Q4 2025 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Inhibrx Biosciences, Inc.'s Q4 2025 revenue and EPS?
Inhibrx Biosciences, Inc. reported revenue of - and diluted EPS of $-2.11 for Q4 2025.
Did Inhibrx Biosciences, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $1.1M by $1.1M. EPS missed the consensus estimate of $-2.08 by $0.03.
How did Inhibrx Biosciences, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $100.0K a year earlier and diluted EPS grew 31.7% from $-3.09.
Where can I find Inhibrx Biosciences, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0002007919-26-000007) and the 10-K periodic report (0002007919-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.